# TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC

Source: [science.org](https://www.science.org/doi/abs/10.1126/sciadv.aec9042?af=R) · 2026-11-18 · Life
Page: https://themorning.science/story/trim28-mediated-sumoylation-of-erg-at-k389-conveys-parp-inhibitor-resistance-by-d0c20dfe00f1422f
Kind: research · Impact: medium

## In brief

- A study in Science Advances reports that TRIM28-mediated SUMOylation of ERG at lysine 389 confers PARP inhibitor resistance in castration-resistant prostate cancer (CRPC).
- The mechanism works by inhibiting 53BP1 expression.
- The paper was published in Science Advances, Volume 12, Issue 47, November 2026.

## Why it matters

The findings identify a molecular pathway linked to resistance against PARP inhibitors in castration-resistant prostate cancer, which may inform future treatment strategies and biomarker research.

## Timeline

- 2026-11-18: Study published in Science Advances (Volume 12, Issue 47)

## Coverage

- [TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC](https://www.science.org/doi/abs/10.1126/sciadv.aec9042?af=R) — science.org, 2026-11-18

Tags: prostate cancer, PARP inhibitors, drug resistance, SUMOylation, 53BP1

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
